After Dropping 94% From Post IPO high from $19.45, a loss of exceeding $3 billion and change, ATAI is in the early stages of a recovery (our opinion) gaining 94%...
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in Australia
Phase I trial will study 20 people to...
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
LIVE QUOTE
Bargain Hunters Dream
View Post
ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
We watched an excellent presentation from management at the Dawson conference and starting our due diligence now. Primary item of our interest is a joint...
Psychedelic Drug Helped People with Alcohol use Disorder Reduce Drinking, Study Shows (Today)
Psilocybin, the ingredient in magic mushrooms, along with talk...
